Senapati, Jayastu
Sasaki, Koji http://orcid.org/0000-0002-9140-0610
Issa, Ghayas C. http://orcid.org/0000-0002-4339-8683
Lipton, Jeffrey H.
Radich, Jerald P. http://orcid.org/0000-0002-1618-230X
Jabbour, Elias http://orcid.org/0000-0003-4465-6119
Kantarjian, Hagop M. http://orcid.org/0000-0002-1908-3307
Article History
Received: 22 February 2023
Revised: 27 March 2023
Accepted: 30 March 2023
First Online: 24 April 2023
Conflict of interest
: Jayastu Senapati -- no conflict of interest. Koji Sasaki -- research funding and honoraria for advisory boards from Novartis. Ghayas Issa-- consulting or advisory role: Novartis, Kura OncologyResearch; research funding: Novartis, Syndax, Kura Oncology. Jeffrey H Lipton—consulting for Bristol Myers Squibb, Novartis, Pfizer, and Takeda; research funding from Bristol Myers Squibb, Novartis, Pfizer, and Takeda; received honorarium from Bristol Myers Squibb, Pfizer, and Takeda. Jerry Radich -- grants from the National Cancer Institute during the conduct of the study; consulting for Novartis, Bristol Myers Squibb, Takeda, Amgen, Cepheid, Bio-Rad, Adaptive, and SeaGen. Elias Jabbour – research grants from AbbVie, Adaptive Biotechnologies, Amgen, Pfizer, and Takeda; consulting fees from AbbVie, Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Genentech, Incyte, Novartis, Pfizer, and Takeda. Hagop Kantarjian -- grants from AbbVie, Amgen, Ascentage, Bristol Myers Squibb, Daiichi Sankyo, ImmunoGen, Jazz, Novartis, and Pfizer; honoraria from AbbVie, Amgen, Aptitude Health, Ascentage, Astellas Health, AstraZeneca, Ipsen Biopharmaceuticals, KAHR Medical Ltd, NOVA Research, Novartis, Pfizer, Precision BioSciences, and Taiho Pharma.